Complete your CME evaluation and claim credits for the ISTH 2023 Congress by following these steps:

DEADLINE: August 31, 2023, 11:59 pm US Eastern Time

 

1. Login to the online Program Planner (login link is on the top right side of the planner page) with your Congress registration ID (this can be found in your registration confirmation email)

2. Once logged in, click on “CME Evaluation” on the left side menu

3. You will be directed to the evaluation site and may be prompted to complete a consent form

4. Complete both the “Overall Evaluation” and individual “Session Evaluations”, make sure your entries are saved and the tasks have a green check mark to indicate that they are complete

 

The ISTH will email personalized CME certificates to those who completed all evaluations by the end of September 2023.

________________________________________________________________________________

​

International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

June 24-28, 2023

 

This program meets the accreditation criteria as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and has been accredited by the Office of Continuing Professional Development, Faculty of Medicine and Health Sciences, McGill University for up to 18.75 Section 1 credits/hours.

 

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

 

Continuing Medical Education (CME) Credits

 

Please read the below with important information regarding continuing medical education credits. 

 

1. CME Credits can ONLY be claimed if CME has been purchased as part of registration. CME can be purchased through Wednesday, June 28th. After June 28th, CME can no longer be purchased. 

2. CME Credits can ONLY be claimed for those attending the congress in-person. CME Credits will NOT be available for attendance and/or viewing of the Virtual or On-Demand sessions. Plenary, State-of-the-Art, and Oral Communication IN-PERSON sessions on Saturday, June 24 – Wednesday, June 28 are the only sessions available to claim credit.

3. You must be scanned into each Plenary, State-of-the-Art, and Oral Communication session that you wish to receive credit for and complete the related session evaluation online.

4. A CME EVALUATION MUST BE COMPLETED BY AUGUST 31, 2023 IN ORDER TO RECEIVE A CME CERTIFICATE.

​

For more information about purchasing CME, email registration@isth.org.

 

 

Learning Objectives – Overall Program

At the conclusion of this activity, participants will be able to …

• Describe coagulation mechanisms and how dysregulation of coagulation, including dysregulation associated with trauma, can lead to either bleeding or thrombosis.

• Describe how bleeding is caused by protein deficiencies or defects in platelet function and how to treat such bleeding with either conventional therapies or newly developed therapeutics.

• Compare how bleeding and thrombosis is different in children and adults.

• Determine how thrombosis is caused by Sars-CoV-2 infection and how to effectively treat such thrombosis.

• Describe how coagulation factors, platelets, and the vessel wall interact and how conditions such as advanced age, cancer, or pregnancy can alter these interactions to promote thrombosis.

• Describe how treatments and new therapeutics will improve medical care for patients with either bleeding or thrombosis.

 

Conflict of Interest Declarations: Scientific Planning Committee (SPC) Members

Local Organizing Committee

Marc Carrier, M.D., Member, The Ottawa Hospital

• I am a member of an advisory board or similar committee (Sanofi, Servier, Bayer, Valeo, BMS, Pfizer and Leo Pharma, January 1st 2019 to “ongoing”. All payments made to my institution)

• I have received payment from a for-profit/not-for-profit organization (Grant funding: Leo Pharma, BMS, and Pfizer, January 1, 2019 to “ongoing”. All payments made to my institution)

Mary Cushman, M.D., Member, University of Vermont Larner College of Medicine

• I am a member of an advisory board or similar committee (International Society on Thrombosis and Haemostasis, 7-2022-present; Hemostasis and Thrombosis Research Committee, 2019-present)

• I have received grants/honoraria from a for-profit/not-for-profit organization (Honoraria, International Society on Thrombosis and Haemostasis for editorship of a journal, Research and Practice in Hemostasis, 2016-present; Many grants from NIH, Decades)

Susan R. Kahn, M.D., Co-Chair, McGill University

• I have received payment from a for-profit/not-for-profit organization (Alexion (honorarium to develop educational materials on PNH and give 2 talks) During 2021 and 2022)

• I have received grants/honoraria from a for-profit/not-for-profit organization (Sanofi Global (honorarium to participate in a health services research project) During 2022)

Patricia Liaw, M.D., Member, McMaster University

• I have received grants/honoraria from a for-profit/not-for-profit organization (Protalix Biotherapeutics (grant), July 2021 to February 2023; Journal of Thrombosis and Haemostasis (honorarium), 2018-present)

David Lillicrap, M.D., Member, Queen’s University

• I am a member of an advisory board or similar committee (Biomarin, 2020-2023; CSL Behring, 2020-2022; Sanofi, 2020-2022; Takeda, 2020-2022)

• I have received grants/honoraria from a for-profit/not-for-profit organization (Biomarin, 2020-2023; Bayer, 2020-2023; CSL-Behring, 2020-2023; Sanofi, 2020-2022)

Davide Matino, M.D., Member, McMaster University

• I have received grants/honoraria from a for-profit/not-for-profit organization (Bayer, Pfizer, Octapharma, Sanofi, Sobi, Novo Nordisk: Jan 2021 to Jan 2023)

• Other (clinical trail) (Bayer, Sanofi, Pfizer, Novo Nordisk, Roche, Spark: Jan 2021 to Jan 2023)

Margaret Rand, M.D., Member, Hospital for Sick Children

• I do not have an affiliation (financial or otherwise) with a for-profit/not-for-profit organization.

Marc Rodger, M.D., Co-Chair, McGill University

• I am a member of an advisory board or similar committee (INVENT, 2016-present)

Sam Schulman, M.D., Member, HHS – General Hospital, McMaster University

• I have received payment from a for-profit/not-for-profit organization (Alexion, Bayer, Boehringer Ingelheim, Baiichi-Sankyo, Octapharma, Sanofi, Servier, Hemostasis Reference Lab, Bristol-Myers Squibb, Pfizer, Canadian Medical Protective Association: Ongoing)

• I have received grants/honoraria from a for-profit/not-for-profit organization (Octapharma – research grant to my university: 2018-2022)

Deborah Siegal, M.D., Member, University of Ottawa, Ottawa Hospital Research Institute

• I have received grants/honoraria from a for-profit/not-for-profit organization (BMS-Pfizer, Servier, Astra Zeneca, Roche: 2019-Present)

​

This program has received an educational grant or in-kind support from: